Crosslinked Polyacrylamide Hydrogel for Exposed Collagen Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cartilage damage, such as transplantation and stem cell therapies, are invasive, provide limited and short-term relief, and have inadequate efficacy, while prophylactic treatments like nutraceuticals lack conclusive evidence of effectiveness. Additionally, existing mechanical barriers for exposed collagen, such as carboxymethylcellulose, can cause allergies, and lubricants like hyaluronic acid have short lifespans and enzymatic degradation issues.
Innovation Solution
The use of biocompatible crosslinked polyacrylamide hydrogel formulations (bPAAGs) that preferentially bind to damaged cartilage and exposed collagen, providing a mechanical barrier, localized therapeutic delivery, and acting as a scaffold for tissue engineering, offering extended release of therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If invasive treatments like cartilage transplantation or stem cell therapy are used, then cartilage repair may be achieved, but the procedures are complex, require harvesting and lab growth of cells, and have limited long-term efficacy
Solution Approach 1:
The patent extracts the essential function of cell-based therapies (providing a scaffold for tissue regeneration) while eliminating the complex cell harvesting, lab culture, and transplantation procedures. The bPAAG hydrogel delivers this function directly as an injectable formulation containing growth factors and scaffold structures, removing the need for separate cell processing steps.
Solution Approach 2:
The bPAAG hydrogel formulation serves multiple functions simultaneously: it acts as a mechanical scaffold, delivers multiple growth factors (PDGF, TGF-beta, IGF-1), provides anti-inflammatory effects, and maintains a moist healing environment. This multi-functionality replaces what previously required multiple separate treatments or procedures.
2Object-affected harmful factors
If carboxymethylcellulose is used as a mechanical barrier for exposed collagen, then protection is provided, but allergic reactions and sensitivities can occur
Solution Approach 1:
The patent changes the chemical composition parameter of the protective barrier material from carboxymethylcellulose to bovine polyacrylamide hydrogel. This parameter change maintains the protective mechanical barrier function while eliminating the allergenic properties associated with carboxymethylcellulose, as evidenced by the absence of allergic reactions in clinical use.
3Ease of operation
If hyaluronic acid is used for viscosupplementation, then lubrication is provided, but the substance has short lifespan and is susceptible to enzymatic degradation
Solution Approach 1:
The bPAAG hydrogel formulation creates a composite material system that combines polyacrylamide polymer network with embedded growth factors and crosslinking agents. This composite structure provides both the lubrication function and extended durability, as the crosslinked hydrogel network resists enzymatic degradation while maintaining lubricating properties.
4Reliability
If frequent therapeutic administration is required, then adequate treatment coverage is achieved, but treatment frequency and patient burden increase
Solution Approach 1:
The bPAAG hydrogel is pre-loaded with growth factors and therapeutic agents during formulation, allowing a single injection to provide sustained release of multiple therapeutics over time. This preliminary incorporation of therapeutics eliminates the need for frequent repeat administrations, as the hydrogel matrix controls gradual release of embedded agents.
Solution Approach 2:
The crosslinked hydrogel structure maintains continuous therapeutic presence at the injection site through controlled diffusion and degradation of the polymer matrix. This continuous action ensures adequate treatment coverage over extended periods (months) without requiring repeated interventions, maintaining therapeutic levels continuously rather than in discrete doses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
bPAAGs provide long-lasting protection and lubrication, reduce the frequency of therapeutic administration, and prevent tissue adhesions, while being non-invasive and suitable for individuals with allergies to HA or CMC, with potential for controlled release of agents over weeks to months.
Implementation Method 1
bPAAGs provide long-lasting protection and lubrication... that preferentially bind to damaged cartilage and exposed collagen
Implementation Method 2
Healthy cartilage also is the body's shock absorber as well as minimizing friction between surfaces and facilitating ease of motion
Data Source
AI summary
The present invention relates to the use of certain polyacrylamide gel formulations to treat conditions where cartilage has degraded and/or where exposed collagen is present. The invention further relates to the prophylactic use of such formulations to prevent degradation, or further degradation, of cartilage and/or collagen. Additionally, the invention also includes substituting such certain polyacrylamide gel formulations in lieu of carboxymethylcellulose, or alternatively HA, in individuals and mammals having allergies, sensitivities, or other adverse reactions to such compounds. Additionally, the invention further relates to the use of the polyacrylamide gel formulations for the controlled release of therapeutic agents and/or as a medical scaffold or matrix for biological therapies.